Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

PURPOSE: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with a favorable safety profile in patients with relapse...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Younes, Anas, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Ramchandren, Radhakrishnan, Bartlett, Nancy L., Cheson, Bruce D., de Vos, Sven, Forero-Torres, Andres, Moskowitz, Craig H., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Kennedy, Dana A., Sievers, Eric L., Chen, Robert
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2012
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646316/
https://ncbi.nlm.nih.gov/pubmed/22454421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.0410
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky